GSK Plc gets EU approval for HIV prevention drug Apretude
GSK Plc announced that its subsidiary ViiV Healthcare got a green light from the European Commission for the company’s HIV prevention medicine.
Drugs
Health
Pharma
Drugs
Health
Pharma
Half of global population not covered by basic health services: WHO, WB
HQ Team September 19, 2023: More than half of the world’s population is still not covered by essential health services, and two billion.
Drugs
Health
Pharma
‘Every hour 1,000 people die of stroke, heart attack due to high blood pressure’
HQ Team September 19, 2023: More than 1,000 people globally die of strokes and heart attacks every hour, mostly due to high blood.
Drugs
Health
Pharma
Pfizer’s oral capsule Litfulo to treat hair loss gets EU approval
HQ Team September 19, 2023: The European Commission granted Pfizer Inc., a marketing authorisation for its once-daily oral capsule to treat hair loss.
Drugs
Health
Pharma
FDA rules Accord’s tacrolimus oral drug not “substitutable” for US market
HQ Team September 19, 2023: The USFDA stated that Accord Healthcare Inc.’s generic tacrolimus oral capsules, meant to treat organ rejection, were no.
Drugs
Health
Pharma
GE Healthcare gets $44 million grant from Bill & Melinda Foundation
HQ Team September 18, 2023: The Bill & Melinda Gates Foundation has given a grant of $44 million to GE Healthcare to create.
Drugs
Health
Pharma
Germany’s BioNTech, CEPI in $90m pact for mpox vaccine
HQ Team September 18, 2023: German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic.
Drugs
Health
Pharma
US cancer patients using alcohol pose new challenge for caretakers
Cancer patients and survivors who drink alcohol make their treatment less effective and raise their chances of the disease returning — an exigency.
Drugs
Health
Pharma
USFDA gives nod for GSK’s Ojjaara bone cancer therapy
The USFDA has approved GSK Plc’s oral therapy to treat anaemia in patients with myelofibrosis, a type of bone cancer.
Drugs
Health
Pharma
EMA recommends stopping sale of GSK’s blood cancer drug in EU
The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.